ArticleLeukemia2026

Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

Florian Simon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.